- Aditxt (ADTX, Financial) regains compliance with Nasdaq's minimum bid price requirement.
- Weekly Update event to provide insights on strategic transactions and subsidiary operations.
- Virtual attendance via Zoom requires registration.
Aditxt, Inc. (ADTX), a social innovation platform focused on healthcare innovations, has announced that it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This key development will be discussed in Aditxt's Weekly Update event, scheduled for today at 11:30 a.m. ET. The virtual event will be accessible via Zoom, with registration required for participation.
The event will also feature updates on the company's operating subsidiaries and provide insights into ongoing strategic transactions. Aditxt's current focus includes immune health and precision health programs, with plans to expand into public health and women's health sectors through strategic partnerships. These initiatives include an Arrangement Agreement with Appili Therapeutics, Inc. (APLI) and a Merger Agreement with Evofem Biosciences, Inc. (EVFM).
Both transactions with Appili and Evofem are subject to several conditions, including shareholder approval and Aditxt raising sufficient capital for closing obligations. The financial commitments include approximately $17 million for each transaction to meet various financial requirements, including the satisfaction of Evofem's senior secured noteholder. Notably, Evofem has announced the cancellation of its stockholders meeting concerning the merger proposal with Aditxt.
